KR970014765A - 신경보호제를 이용한 이명의 치료 - Google Patents

신경보호제를 이용한 이명의 치료 Download PDF

Info

Publication number
KR970014765A
KR970014765A KR1019960039978A KR19960039978A KR970014765A KR 970014765 A KR970014765 A KR 970014765A KR 1019960039978 A KR1019960039978 A KR 1019960039978A KR 19960039978 A KR19960039978 A KR 19960039978A KR 970014765 A KR970014765 A KR 970014765A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutical composition
hydroxy
chroman
pharmaceutically acceptable
Prior art date
Application number
KR1019960039978A
Other languages
English (en)
Inventor
스티븐 비 샌드스
Original Assignee
스피겔 알렌 제이
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스피겔 알렌 제이, 화이자 인코포레이티드 filed Critical 스피겔 알렌 제이
Publication of KR970014765A publication Critical patent/KR970014765A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 하기 화학실 (1)의 화합물 또는 그의 약학적으로 허용가능한 염의 치료 효과량을 포함하는 포유동물의 이명 치료용 약학 조성물에 관한 것이다 ;
상기 식에서 , R1내지 R6은 본원에 정의되어 있는 바와 같다.

Description

신경보호제를 이용한 이명의 치료
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 하기 화학식 (1)의 화합물 또는 그의 약학적으로 허용가능한 염의 치료 효과량을 약학적으로 허용가능한 비히클 또는 희석제와 함께 포유동물의 이명 치료용 약학 조성물 :
    상기 식에서, (a) R2및 R5는 별개이고, R1, R2, R3및 R4는 각각 독립적으로, 수소, C1-C6알킬, 할로, CF3, OH 또는 -OR7이고, R5는 메틸 또는 에틸이거나: 또는 (b) R2및 R5는 함께이고, 크로만-4 올 고리를 형성하고, Rl, R3및 R4는 각각 독립적으로 수소, C1-C6알킬, 할로, CF3, OH 또는 -OR7이고; R6은
    이고; R7은 메틸, 에틸, 이소프로필 또는 n-프로필이고; R8은 C1-C6알킬, 할로 또는 CF3로 구성된 군에서 독립적으로 선택된 3개 이하의 치환체로 선택적으로 치환된 페닐이고, X는 O, S 및 (CH2)n이고; n은 0, 1, 2 또는 3이다.
  2. 제1항에 있어서, R2및 R5가 별개이고; R2및 R3가 수소이고; R6이이고; R8이 페닐, 4-할로페닐 또는 4-트리플루오로메틸페닐인 약학 조성물.
  3. 제2항에 있어서, R5가 1S*, 2S*상대적 입체이성질성을 갖는 메틸인 약학 조성물.
  4. 제1항에 있어서, R2및 R5가 함께이고, 크로만-4-올 고리를 형성하는 약학 조성물.
  5. 제4항에 있어서, 상기 크로만-4-올 고리의 C-3 및 C-4 위치에서 3R*, 4S*상대적 입체이성질성을 갖는 약학 조성물.
  6. 제5항에 있어서, R6이이고; R8이 페닐 또는 4-할로페닐인 약학 조성물.
  7. 제1항에 있어서, 상기 화합물이 (3R,4S)-3-[4-(4-플루오로페닐)-4-하이드록시-피페리딘-1-일]-크로만-4,7-디올, (1S,2S)-1-(4-하이드록시페닐)-2-(4-하이드록시 -4-페닐피페리딘-1-일)-1-프로판올, 및 이들 화합물의 약학적으로 허용가능한 염으로 구성된 군에서 선택되는 약학 조성물.
  8. 제7항에 있어서, 상기 화합물이 (1S,2S)-1-(4-하이드록시페닐)-2-(4-하이드록시-4-페닐피페리딘-1-일)-1-프로판올, 이 화합물의 타트타레이트 염 또는 이 화합물의 메실레이트 염인 약학 조성물.
  9. 제7항에 있어서, 상기 화합물이 (1S,2S)-1-(4-하이드록시페닐)-2-(4-하이드록시-4-페닐피페리딘-1-일)-1-프로판올의 메실레이트 염 삼수화물인 약학 조성물.
  10. 제7항에 있어서, 상기 화합물이 (3R,4S)-3-[4-(4-플루오로페닐)-4-하이드록시-피페리딘-1-일]-크로만-4,7-디올, 및 이 화합물의 타르타레이트, 락테이트 및 만델레이트 염으로 구성된 군에서 선택되는 약학 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960039978A 1995-09-15 1996-09-14 신경보호제를 이용한 이명의 치료 KR970014765A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US385595P 1995-09-15 1995-09-15
US60/003,855 1995-09-15

Publications (1)

Publication Number Publication Date
KR970014765A true KR970014765A (ko) 1997-04-28

Family

ID=21707919

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960039978A KR970014765A (ko) 1995-09-15 1996-09-14 신경보호제를 이용한 이명의 치료

Country Status (17)

Country Link
US (1) US5716961A (ko)
EP (1) EP0768086B1 (ko)
JP (1) JP3038155B2 (ko)
KR (1) KR970014765A (ko)
CN (1) CN1104892C (ko)
AT (1) ATE224714T1 (ko)
AU (1) AU697679B2 (ko)
CA (1) CA2185512C (ko)
DE (1) DE69623899T2 (ko)
DK (1) DK0768086T3 (ko)
ES (1) ES2181853T3 (ko)
IL (1) IL119207A (ko)
MY (1) MY119375A (ko)
NZ (1) NZ299376A (ko)
PT (1) PT768086E (ko)
TW (1) TW450807B (ko)
ZA (1) ZA967746B (ko)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
TR200102876T2 (tr) * 1999-04-07 2006-12-21 Pfizer Products Inc. Bileşim tedavilerinde CYP2D6 önleyicilerinin kullanılması.
US6784200B2 (en) * 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
US6586446B1 (en) 1999-10-15 2003-07-01 Bristol-Myers Squibb Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
YU27801A (sh) * 2000-04-28 2003-04-30 Pfizer Products Inc. Postupak za dobijanje trihidrata mezilatne soli 1-(4- hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanola i korisnih intermedijera
DE10048969A1 (de) * 2000-08-23 2002-03-14 Mueller Schwefe Gerhard Verwendung von Flupirtin zur Tinnitusbehandlung
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
UA73619C2 (en) * 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
SE0100344D0 (sv) * 2001-02-05 2001-02-05 Jan Nordmark New Use
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US7589110B2 (en) * 2002-09-06 2009-09-15 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US7785653B2 (en) * 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
NZ566062A (en) * 2005-09-28 2009-08-28 Auris Medical Ag Pharmaceutical compositions for the treatment of inner ear disorders comprising an arylcycloalkylamine such as ketamine and a biocompatible polymer
US20090069419A1 (en) * 2007-09-07 2009-03-12 Bernd Jandeleit Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
WO2011145062A1 (en) 2010-05-21 2011-11-24 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
EP2621475A1 (en) 2010-10-02 2013-08-07 Link Research&Grants Corporation Treatment of tinnitus and related auditory dysfunctions
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
JPH0788355B2 (ja) * 1991-04-18 1995-09-27 フアイザー・インコーポレイテツド フェノール性２―ピペリジノ―１―アルカノールのプロドラグエステル
EP0542689B1 (en) * 1991-11-15 1998-09-23 Phafag Aktiengesellschaft Use of 1-(aminoalkyl)-3-quinoxaline-2-on derivatives for the preparation of neuroprotective compositions
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
TW450807B (en) 2001-08-21
NZ299376A (en) 2000-07-28
DE69623899D1 (de) 2002-10-31
EP0768086B1 (en) 2002-09-25
CA2185512A1 (en) 1997-03-16
CN1149454A (zh) 1997-05-14
DE69623899T2 (de) 2003-01-23
JPH09124482A (ja) 1997-05-13
IL119207A0 (en) 1996-12-05
AU697679B2 (en) 1998-10-15
CA2185512C (en) 2000-08-08
ATE224714T1 (de) 2002-10-15
ES2181853T3 (es) 2003-03-01
US5716961A (en) 1998-02-10
ZA967746B (en) 1998-03-13
AU6563596A (en) 1997-03-20
JP3038155B2 (ja) 2000-05-08
IL119207A (en) 2004-05-12
DK0768086T3 (da) 2002-10-14
MY119375A (en) 2005-05-31
CN1104892C (zh) 2003-04-09
MX9603819A (es) 1997-07-31
EP0768086A1 (en) 1997-04-16
PT768086E (pt) 2003-01-31

Similar Documents

Publication Publication Date Title
KR970014765A (ko) 신경보호제를 이용한 이명의 치료
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
KR970705542A (ko) 신경보호성 3-(피페리디닐-1)-크로만-4,7-디올 및 1-(4-하이드로페닐)-2-(피페리디닐-1)-알칸올 유도체(neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
NO991700L (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
JP2007517846A5 (ko)
RU97102362A (ru) Нейрозащитные производные 3-(пиперидинил-1)-хроман-4,7-диола и 1-(4- гидроксифенил)-2-(пиперидинил-1)-алканола
ATE282410T1 (de) Thyromimetika als mittel gegen fettleibigkeit
PT97710A (pt) Processo para a preparacao de novos derivados da amino-piperidina,da amino-pirrolidina e de amino-per-hidroazepina
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
KR930701402A (ko) N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
FI952481A (fi) Substituoituja 3-(aminoalkyyliamino)-1,2-bentsisoksatoleja ja niihin liittyviä yhdisteitä
PT863136E (pt) Derivados de azetidina e de pirrolidina
PT992509E (pt) Novos derivados macrolidos
DK0984019T3 (da) C11-carbamater fra antibakterielle macrolider
BR8303091A (pt) Processo para a preparacao de derivados de hidrozialcinil-azolilo, composicoes fungicidas, processos para o combate de fungos e para a preparacao de composicoes
KR910004191A (ko) 신질환치료제
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
KR960704878A (ko) 광학 활성 이미다졸리딘온 유도체 및 이의 제조방법 (Optically active imidazolidinone derivative and process for producing the same)
KR900012925A (ko) 인돌 유도체
KR960702456A (ko) 4-(p-플로오로페닐)-3-[(3,4-(메틸렌디옥시)페녹시)메틸]피페리딘의 n-p-할로벤조일메틸 유도체(n-p-halobenzoylmethyl derivatives of 4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]piperidine)
PT1209166E (pt) Novos derivados de a-500359
FI95243B (fi) Typpiheterosyklien substituoidut 2-propenyylijohdannaiset
KR970705385A (ko) 뼈 치료법 및 골절 치유법(methods for bone healing and fracture repair)
KR920700640A (ko) 혈당 저하제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application